Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsIsothiocyanates Are Promising Compounds against Oxidative Stress, Neuroinflammation and Cell Death that May Benefit Neurodegeneration in Parkinson's DiseaseL-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa historyBehavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in miceCell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia.Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.Chronic levodopa administration followed by a washout period increased number and induced phenotypic changes in striatal dopaminergic cells in MPTP-monkeysPharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine.Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia.Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.Depressive-like behavior observed with a minimal loss of locus coeruleus (LC) neurons following administration of 6-hydroxydopamine is associated with electrophysiological changes and reversed with precursors of norepinephrineSerotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice.M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced DyskinesiaCritical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease.Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia.L-DOPA and graft-induced dyskinesia: different treatment, same story?Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.Heterotopic Mucosal Grafting Enables the Delivery of Therapeutic Neuropeptides Across the Blood Brain Barrier.Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease.Differential Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on Motor Behavior and Dopamine Levels at Brain Regions in Three Different Mouse Strains.Comparison of 6-hydroxydopamine lesions of the substantia nigra and the medial forebrain bundle on a lateralised choice reaction time task in mice.Behavioural recovery on simple and complex tasks by means of cell replacement therapy in unilateral 6-hydroxydopamine-lesioned mice.Functional single-walled carbon nanotubes 'CAR' for targeting dopamine delivery into the brain of parkinsonian mice.Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats
P2860
Q21129423-9F565182-4587-4F21-867B-1BE2A148DFA3Q28079206-244272F5-EF85-4081-B7DC-3C2B61BB1400Q28602694-FB8C95F6-9428-48D2-B144-FF2249EB3DFFQ30454614-B5956377-1716-482E-9493-7D72F6B51E14Q30512976-54835EBD-62B3-444E-8AE0-320A20705ED5Q30528818-30E41054-2998-44C8-8D57-511A53ED3B41Q30650489-EC52F278-6767-4897-8143-812AC08C9F6DQ30836713-6DB6B303-ABB5-43BD-AEFD-2CE883BC62ECQ34506001-6024A9A2-9474-41CA-BB77-234262CE0BB3Q35154720-483B9644-D8D8-455E-8046-28A2338C3656Q35324207-AB77BDEA-6AB0-4D8D-8BF9-63545A495708Q35574934-DAE7BA87-AFD3-4F97-A4DD-D5AA8DB0C8BFQ35738538-09E73FAE-6794-430D-ABAF-CBDA0909738AQ36663572-9A1F856F-1223-40B4-9DAA-65621846BD5CQ36680671-EAA33540-6460-49B5-8A92-62A4FE57C93BQ36892615-85A58D83-CAE5-4D6D-A8EB-2F40ECDE935FQ37385099-0884A554-2CDF-4472-AC8C-8F8A8DCBB7D2Q37674269-3FAC4882-9849-419D-B530-8AACD6C3E704Q38119449-D0ABFD5F-DD6A-4A0A-9DE8-C98292F625F2Q38629277-3757760B-318D-4D72-9C73-8C14C355B47EQ38836658-40CE69E2-DAAF-4FFA-B1CD-542B5C55415DQ41904397-6B6E2B3A-2E10-4325-8D9F-98DEC4DA0BDAQ43242399-A9987ABB-4FFF-4734-A75D-7F542642FBF0Q45053410-CB69C3E5-0A1C-4588-8420-89F82540E2ADQ45363661-176021AE-4036-4157-A235-7692AEEE46B5Q46333318-CF42D5AF-C70E-47E4-963F-2E3C1D5BA991Q48113961-19355901-23F4-43DA-9184-969BEBD8BED3Q53096926-B295B941-3F04-4E0E-87E9-C87075C515ABQ58782231-2DE00FBC-FB13-43BF-AADE-BBE724108B7F
P2860
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Impact of the lesion procedure ...... model of Parkinson's disease.
@ast
Impact of the lesion procedure ...... model of Parkinson's disease.
@en
type
label
Impact of the lesion procedure ...... model of Parkinson's disease.
@ast
Impact of the lesion procedure ...... model of Parkinson's disease.
@en
prefLabel
Impact of the lesion procedure ...... model of Parkinson's disease.
@ast
Impact of the lesion procedure ...... model of Parkinson's disease.
@en
P2093
P1476
Impact of the lesion procedure ...... e model of Parkinson's disease
@en
P2093
Alessandra Recchia
Daniel Andersson
Hans Nissbrandt
M Angela Cenci
Nataljia Popovic
P304
P356
10.1016/J.NBD.2011.01.024
P577
2011-02-19T00:00:00Z